BCRX Biocryst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCRX

Price (delayed)

$7.86

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$2.39B

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...

Highlights
Biocryst Pharmaceuticals's gross profit has increased by 24% YoY and by 7% from the previous quarter
BCRX's revenue is up by 23% YoY and by 7% QoQ
Biocryst Pharmaceuticals's quick ratio has decreased by 37% YoY but it has increased by 11% QoQ
BCRX's equity is down by 45% year-on-year and by 4.5% since the previous quarter
BCRX's debt is up by 13% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biocryst.com
Peers: RGEN SRPT NNVC NVAX

Key stats

What are the main financial stats of BCRX
Market
Shares outstanding
206.38M
Market cap
$1.62B
Enterprise value
$2.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.72
Earnings
Revenue
$355.4M
EBIT
-$103.23M
EBITDA
-$101.68M
Free cash flow
-$103.56M
Per share
EPS
-$1.07
Free cash flow per share
-$0.5
Book value per share
-$2.31
Revenue per share
$1.72
TBVPS
$2.27
Balance sheet
Total assets
$467.89M
Total liabilities
$944.06M
Debt
$852.9M
Equity
-$476.17M
Working capital
$327.18M
Liquidity
Debt to equity
-1.79
Current ratio
3.73
Quick ratio
3.33
Net debt/EBITDA
-7.54
Margins
EBITDA margin
-28.6%
Gross margin
98.6%
Net margin
-58.7%
Operating margin
-25.3%
Efficiency
Return on assets
-40.9%
Return on equity
N/A
Return on invested capital
-9.3%
Return on capital employed
-29.7%
Return on sales
-29%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
4.11%
1 week
10.08%
1 month
27.18%
1 year
-0.76%
YTD
31.22%
QTD
27.18%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$355.4M
Gross profit
$350.28M
Operating income
-$89.78M
Net income
-$208.59M
Gross margin
98.6%
Net margin
-58.7%
The operating margin has grown by 42% YoY and by 19% from the previous quarter
BCRX's operating income is up by 29% YoY and by 13% QoQ
BCRX's net margin is up by 25% YoY and by 14% QoQ
Biocryst Pharmaceuticals's gross profit has increased by 24% YoY and by 7% from the previous quarter

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
4.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.72
BCRX's EPS is up by 12% YoY and by 9% from the previous quarter
BCRX's equity is down by 45% year-on-year and by 4.5% since the previous quarter
The P/S is 75% lower than the 5-year quarterly average of 17.5 but 18% higher than the last 4 quarters average of 3.7
BCRX's revenue is up by 23% YoY and by 7% QoQ

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS is up by 30% YoY and by 19% from the previous quarter
The ROIC rose by 30% YoY and by 14% QoQ
The company's return on assets rose by 6% QoQ and by 3.8% YoY

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 50% lower than its total liabilities
Biocryst Pharmaceuticals's quick ratio has decreased by 37% YoY but it has increased by 11% QoQ
Biocryst Pharmaceuticals's current ratio has decreased by 35% YoY but it has increased by 13% from the previous quarter
BCRX's equity is down by 45% year-on-year and by 4.5% since the previous quarter
BCRX's debt to equity is up by 22% year-on-year and by 3.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.